These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 25466196)

  • 21. c-erbB-2 as a possible target for the use of magnetic nanoparticles in breast cancer cells.
    Silva-Escobedo JG; Sanchez-Monroy V; Rojas-Lopez M; Lopez-Cruz J; González CA
    IEEE Trans Nanobioscience; 2014 Sep; 13(3):300-7. PubMed ID: 25014961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
    Menendez JA; Ropero S; Lupu R; Colomer R
    Oncol Rep; 2004 Jun; 11(6):1241-52. PubMed ID: 15138562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant λ bacteriophage displaying nanobody towards third domain of HER-2 epitope inhibits proliferation of breast carcinoma SKBR-3 cell line.
    Shoae-Hassani A; Mortazavi-Tabatabaei SA; Sharif S; Madadi S; Rezaei-Khaligh H; Verdi J
    Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):75-83. PubMed ID: 23224340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M; Yao J; Yu D
    Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N⁴-Phenyl-substituted 2-acetylpyridine thiosemicarbazones: cytotoxicity against human tumor cells, structure-activity relationship studies and investigation on the mechanism of action.
    Soares MA; Lessa JA; Mendes IC; Da Silva JG; Dos Santos RG; Salum LB; Daghestani H; Andricopulo AD; Day BW; Vogt A; Pesquero JL; Rocha WR; Beraldo H
    Bioorg Med Chem; 2012 Jun; 20(11):3396-409. PubMed ID: 22564383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
    Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells.
    Maleki S; Dorokhova O; Sunkara J; Schlesinger K; Suhrland M; Oktay MH
    Diagn Cytopathol; 2013 Oct; 41(10):864-70. PubMed ID: 23447357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells.
    Rahman KM; Aranha O; Glazyrin A; Chinni SR; Sarkar FH
    Oncogene; 2000 Nov; 19(50):5764-71. PubMed ID: 11126363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.
    Yurekli BS; Karaca B; Cetinkalp S; Uslu R
    Med Hypotheses; 2009 Oct; 73(4):606-7. PubMed ID: 19560877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
    Kang H; Mansel RE; Jiang WG
    Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein expression of G-protein inwardly rectifying potassium channels (GIRK) in breast cancer cells.
    Dhar MS; Plummer HK
    BMC Physiol; 2006 Aug; 6():8. PubMed ID: 16945134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-breast cancer activity of heteroaryl chalcone derivatives.
    Solomon VR; Lee H
    Biomed Pharmacother; 2012 Apr; 66(3):213-20. PubMed ID: 22440895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo.
    Greene LM; Fleeton M; Mulligan J; Gowda C; Sheahan BJ; Atkins GJ; Campiani G; Nacci V; Lawler M; Williams DC; Zisterer DM
    Oncol Rep; 2005 Nov; 14(5):1357-63. PubMed ID: 16211309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
    Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
    Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu-Positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications.
    Brown RE
    Ann Clin Lab Sci; 2002; 32(1):12-21. PubMed ID: 11848612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting.
    Aydın RS
    J Biomed Mater Res A; 2013 May; 101(5):1405-15. PubMed ID: 23086911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.